Baseline immune profile by CyTOF can predict response to an investigational adjuvanted vaccine in elderly adults
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Baseline immune profile by CyTOF can predict response to an investigational adjuvanted vaccine in elderly adults ; volume:16 ; number:1 ; day:5 ; month:6 ; year:2018 ; pages:1-12 ; date:12.2018
Journal of translational medicine ; 16, Heft 1 (5.6.2018), 1-12, 12.2018
- Classification
-
Medizin, Gesundheit
- Creator
-
Lingblom, Christine M. D.
- Contributor
-
Kowli, Sangeeta
Swaminathan, Nithya
Maecker, Holden T.
Lambert, Stacie L.
SpringerLink (Online service)
- DOI
-
10.1186/s12967-018-1528-1
- URN
-
urn:nbn:de:101:1-2018081118490873632558
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2024, 7:18 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lingblom, Christine M. D.
- Kowli, Sangeeta
- Swaminathan, Nithya
- Maecker, Holden T.
- Lambert, Stacie L.
- SpringerLink (Online service)
Other Objects (12)
Adjuvanted infuenza vaccine dynamics
Adjuvanted influenza vaccine dynamics
Cytomulate: accurate and efficient simulation of CyTOF data
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation
Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020
Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
A self-adjuvanted VLPs-based Covid-19 vaccine proven versatile, safe, and highly protective
A modular and self-adjuvanted multivalent vaccine platform based on porcine circovirus virus-like nanoparticles
Efficacy of an inactivated and adjuvanted “ZULVAC®8 OVIS” vaccine produced using single-use bioreactors
Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA
Adjuvanted infuenza vaccine dynamics
Adjuvanted influenza vaccine dynamics
Cytomulate: accurate and efficient simulation of CyTOF data
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation
Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020
Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
A self-adjuvanted VLPs-based Covid-19 vaccine proven versatile, safe, and highly protective
A modular and self-adjuvanted multivalent vaccine platform based on porcine circovirus virus-like nanoparticles
Efficacy of an inactivated and adjuvanted “ZULVAC®8 OVIS” vaccine produced using single-use bioreactors
Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA
Adjuvanted infuenza vaccine dynamics
Adjuvanted influenza vaccine dynamics
Cytomulate: accurate and efficient simulation of CyTOF data
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation
Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020
Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
A self-adjuvanted VLPs-based Covid-19 vaccine proven versatile, safe, and highly protective
A modular and self-adjuvanted multivalent vaccine platform based on porcine circovirus virus-like nanoparticles
Efficacy of an inactivated and adjuvanted “ZULVAC®8 OVIS” vaccine produced using single-use bioreactors